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Abstract. Translation of nutrient stimuli through
intracellular signaling is important for adaption and
regulation of metabolic processes, while deregulation
by either genetic or environmental factors predisposes
towards the development of metabolic disorders.
Besides providing energy, fatty acids act as prominent
signaling molecules by altering cell membrane struc-
tures, affecting the lipid modification status of pro-
teins, and by modulating ligand-activated nuclear
receptor activity. Given their highly hydrophobic
nature, fatty acids in the aqueous intracellular com-
partment are bound to small intracellular lipid binding
proteins which function as intracellular carriers of
these hydrophobic components. This review describes
recent advances in identifying intracellular pathways
for cytosolic fatty acid signaling through ligand-
activated receptors by means of small intracellular
lipid binding proteins. The mechanism behind intra-
cellular fatty acid transport and subsequent nuclear
receptor activation is an emerging concept, and
advances in understanding this process provide new
potential therapeutic targets towards the treatment of
metabolic disorders.
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Introduction
The dramatic increase in obesity and diabetes in
westernized countries over the last years has led to a
change in dietary awareness, which in turn led to the
development of fat-free foods that contain little or no
fat. While the reduction of saturated and trans-fatty
acids is extremely beneficial for human health from a
nutritional point of view, several types of mono- and
polyunsaturated fatty acids are an important, even
essential part of a balanced diet. Two prominent
members of this group of fatty acids are linoleic acid
and a-linolenic acid, which cannot be endogenously
synthesized and are important building blocks for a
wide variety of complex lipids and hormones [1–3].
These fatty acids as well as their derivatives have
therefore been termed essential fatty acids (EFAs).
The importance of EFAs was demonstrated in several
epidemiological studies, which showed that clinical
symptoms of EFA deficiency include changes in brain
and body weight, increased susceptibility to infections
and degenerative changes in kidneys, lungs and liver
[2–6]. On the other hand epidemiological evidence
supports the notion that high intake of EFAs protects
against coronary heart disease and diabetes [7, 8].
EFA deficiency has been recognized and described as
prevalent in non-westernized countries, and often is
associated with protein-energy malnutrition. How-
ever, some reports speculate that a high number of
people suffer from EFA deficiency in the United
States and other westernized countries [9]. The
reasons for this deficiency are attributed either to
complete absence of fat in the diet or a diet containing
solely saturated fats, proteins and carbohydrates.
How do EFAs in general and polyunsaturated fatty
acids in particular affect cellular metabolism to such
an extent that they are implicated in a wide variety of
diseases?One reason is that these fatty acids as well as
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their derivatives are precursors for complex lipids and
endogenous signaling factors. Second, they are also
potent regulators of gene transcription through acti-
vation of ligand-induced nuclear receptors. Thus,
these fatty acids serve as important signal transduction
molecules that induce pathways involved in fatty acid
trafficking, metabolism and conversion of lipids,
thereby regulating whole-body metabolism.
The family of peroxisome proliferators-activated
receptors
Peroxisome proliferators-activated receptors
(PPARs) were first identified by Issemann and
Green in 1990, when they reported the cloning and
characterization of ligand-activated nuclear transcrip-
tion factors [10]. The name of this family of tran-
scription factors was derived from the fact that PPARs
are activated by peroxisome proliferators (PPs), a
class of xenobiotics, including hypolipidemic drugs
like fibrates, which induce proliferation of peroxi-
somes in hepatocytes [11–14]. It very quickly became
evident that not only are PPARs activated by xeno-
biotics, but also that fatty acids are potent activators of
these transcription factors, thus establishing the role
of PPARs as fatty acid sensors [15–19]. To date, three
PPAR subtypes have been described, namely PPARa,
PPARb (also designated PPARd, NUC1 or FAAR)
and PPARg. All three factors show a distinct tissue
distribution pattern. PPARa is highly expressed in
liver, kidney, testis and skeletal muscle, while PPARg
is mainly expressed in adipose tissue and to a lesser
extent in the large intestine and spleen. PPARb in
contrast to its family members is expressed ubiqui-
tously [18, 19]. The members of the PPAR family
share a domain structure which is commonly found in
ligand-activated hormone receptors, constituting of a
N-terminal A/B domain containing a ligand-inde-
pendent transactivation function (AF-1), a C domain
functioning as aDNAbinding domain (DBD), a hinge
D domain connecting the E/F domain, which contains
the ligand binding domain (LBD), and a ligand-
dependent transactivation function (AF-2) [20, 21].
All three subtypes have in common the ability to
heterodimerize with retinoid X receptors (RXRs) to
activate gene transcription. The PPAR/RXR hetero-
dimer interacts in target genes with PPAR response
elements (PPREs). Consensus PPREs are direct
repeats (DRs) of AGGTCA separated by one nucleo-
tide (DR1), with a 5’ extension of AACTwhich allows
for additional specificity [22, 23].
Interestingly, PPAR subtypes vary not only with
respect to tissue expression but also in their ability
to bind and be activated by ligands. The LBDs of the
three PPAR subtypes have a divergent amino acid
sequence, thus allowing a broad specificity of ligands
[24]. As mentioned above, in addition to xenobiotics
PPARs can bind natural occurring fatty acids and fatty
acid derivatives. Natural ligands of PPARa, b and g
are a variety of long-chain fatty acids and, in
particular, polyunsaturated fatty acids, such as doco-
sahexaenoic acid, EPA, linoleic acid, linolenic acid
and arachidonic acid, with varying degrees of affinity
depending on the method of analysis (Table 1). Fatty
acid metabolites that have been shown to activate
PPARs are the oxidized metabolites of linoleic acid
like 9-hydroxy-octadecadienoic acid (9-HODE) and
13-HODE, which bind and activate both PPARa and
PPARg [25, 26]. Furthermore, the prostaglandin 15-
deoxy-D12,14 PGJ2 was identified as a specific ligand
of PPARg [27, 28].
PPARs have been shown to be important regulators of
whole-body glucose to lipid metabolism. While the
complete description of target genes and physiological
functions is beyond the scope of this review, mouse
models with targeted deletions of the three PPAR
subtypes should be mentioned here, as they can be
used to describe the major physiological functions of
PPARs. The generation of PPARa-deficient mice
confirmed the role of PPARa in peroxisome bio-
genesis and fatty acid b-oxidation in the liver [29–32].
PPARa-deficient mice fail to exhibit peroxisome
proliferation or activation of fatty acid oxidation
target genes when exposed to PPARa agonists.
Furthermore, these mice accumulate increased hep-
atic triglycerides in response to feeding. During
fasting these mice develop severe hypoglycemia due
to the fact that they cannot derive energy from fatty
acids due to impaired b-oxidation [29, 30, 32].
In contrast to PPARa, PPARg-deficient mice die
during intra-uterine development owing to defects in
the placenta, thus limiting research to the study of
heterozygous PPARg mice and tissue-specific dele-
tions of this receptor. Interestingly, even though
PPARgwas shown in cell culture to be a key regulator
of adipogenesis, heterozygous mice on a normal
commercial diet showed no effect on adipose tissue
accretion. Rather, PPARg heterozygous mice dis-
played a higher insulin-stimulated glucose disposal
rate as well as reduced levels of plasma insulin during
glucose tolerance tests and enhanced insulin-medi-
ated suppression of hepatic glucose production in
comparison to wild-type mice [33]. When challenged
by a high fat diet, PPARg heterozygous mice exhibit
less adipose tissue generation, concomitant with
increased insulin sensitivity in comparison to their
wild-type counterparts [33]. Targeted deletion of
PPARg in adipose tissue resulted inmarked adipocyte
hypocellularity and hypertrophy, elevated levels of
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plasma free fatty acids and triglyceride, and decreased
levels of plasma leptin [34]. In addition, these mice
have increased hepatic gluconeogenesis and insulin
resistance. Despite these defects, blood glucose,
glucose and insulin tolerance, and insulin-stimulated
skeletal muscle glucose uptake were all comparable to
those of control mice. However, targeted mice were
significantly more susceptible to high-fat diet-induced
steatosis, hyperinsulinemia and insulin resistance [34].
In contrast to the well-established roles of PPARg and
PPARa in lipid metabolism, less is known of PPARb
in regulation of lipid and glucose metabolism. It was
recently demonstrated that targeted activation of
PPARb in adipose tissue induces expression of genes
required for fatty acid oxidation and energy dissipa-
tion, which in turn leads to improved lipid profiles and
reduced adiposity. Mice overexpressing PPARb in
adipose tissue are completely resistant to both high-fat
diet-induced and genetically predisposed obesity. In
accordance, PPARb-deficient mice challenged with a
high-fat diet show reduced energy uncoupling and are
prone to obesity [35]. Activation of PPARb in
adipocytes and skeletal muscle cells promotes fatty
acid oxidation and utilization, suggesting that PPARb
has a role more similar to PPARa by regulating lipid
catabolism rather than PPARg, which affects adipo-
cyte differentiation and lipid storage [36, 37].
Binding and activation of PPARs through hydrophilic
xenobiotic compounds is easily explained and under-
stood; however, binding and activation of PPARs
through naturally occurring fatty acids poses a prob-
lem, as fatty acids, which are by nature hydrophobic
molecules, are not readily available in their free form
because of their insolubility in aqueous cellular
compartments. It became evident in recent years
that a transport system for these insoluble compounds
exists to provide receptors with ligands for target gene
activation. This mechanism is represented by a class of
small lipid binding proteins (iLBPs) that are found
intracellularly in a wide variety of tissues and have
been shown to bind and transport fatty acids.
Fatty acid binding proteins
Members of this family are the soluble 14–15-kDa
iLBPs, which bind type-specifically retinoids, fatty
acids and bile acids in a non-covalentmanner. To date,
14 different cytoplasmic subtypes have been identi-
fied. The group of iLBPs contains the family of fatty
acid binding proteins (FABPs), which so far encom-
passes 8 members [38–40]. Expression of FABPs
occurs in a regulated and tissue-specific manner, and
their putative functions include shuttling of fatty acids
to specific enzymes and cellular compartments, mod-
ulation of intracellular lipid metabolism and regula-
tion of gene expression [41–43]. A growing body of
experimental evidence has defined the roles of these
proteins in mammalian physiology.
Liver FABP (L-FABP) is abundantly found in hep-
atocytes but is also expressed in other tissues, includ-
ing the stomach, pancreas, intestine and kidney [44].
The L-FABP gene promoter contains a PPRE, and it
was shown that L-FABP is a direct target of PPARa
Table 1. Ligand binding of natural and synthetic compounds to different PPAR subtypes. The table is a compilation of binding data [27, 28,
47, 79, 83–91].
n.b., no binding; n.d. not measured; + – +++ indicates increasing binding affinity.
Ligand PPARa PPARb PPARg
Palmitic acid (16:0) n.b. – + + +
Stearic acid (18:0) n.b – + + +
Palmitoleic acid (16:1) + n.d. n.d.
Oleic acid (18:1) ++ – +++ + +
Linoleic acid (18:2) +++ + – ++ ++
Linolenic acid (18:3) +++ + – ++ ++
AHA (20:4) + – ++ + +
DHA (20:4) + – ++ n.b – + ++
Phytanic acid +++ n.b. n.b.
15d-D12,14-PGJ2 n.b. n.b. +++
Wy14,643 +++ n.b. n.b. – +
ETYA +++ +++ +
Bezfibrate + – ++ ++ – +++ n.b.
LtB4 ++ n.b. n.b.
Troglitazon n.b. + ++ – +++
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[45–49]. Furthermore, messenger RNA levels are
increased by fatty acids, dicarboxylic acids and
retinoic acid as well [50]. Unlike the other members
of the FABP family, L-FABP is able to bind two
ligands simultaneously [51–53]. Peroxisome prolifer-
ators in general bind L-FABP with low affinity,
whereas the fatty acids are boundwith varying affinity,
depending on length and degree of saturation (Table
2). The main known molecular function of L-FABP is
the reversible binding of hydrophobic ligands, which
correlates with fatty acid metabolism in vivo. In line
with this, several changes in fatty acid metabolism in
correlation with intracellular L-FABP concentration
have been reported in vitro, including regulation of
fatty acid uptake and b-oxidation [54–57].
The adipocyteFABP (A-FABP, also known as ap2 and
ALBP)was first identified in adipose tissue, where it is
an abundant cytoplasmic protein [58, 59]. A-FABP
has been shown to bind both saturated and unsatu-
rated fatty acids with similar affinities. In addition to
fatty acids, it was shown to bind troglitazone, a potent
antidiabetic PPARg activator. No binding was ob-
served for other PPARg ligands such as prostaglandins
(Table 2). Expression of A-FABP is highly regulated
during differentiation of adipocytes, and itsmessenger
RNA is transcriptionally controlled by fatty acids [60].
Recent studies in A-FABP-deficient mice have shown
that A-FABP impacts several aspects of themetabolic
syndrome. First, targeted disruption of A-FABP in
mice reduces the hyperinsulinemia and insulin resist-
ance associated with dietary or genetic obesity [61,
62]. Second, A-FABP contributes to improved sys-
temic glucose and lipid metabolism in the setting of
dietary or genetic obesity and influences the rate of
adipocyte lipolysis [61, 62]. Recent studies have
demonstrated that A-FABP plays an important role
inmacrophagemetabolism and that it protects macro-
phages from the excess uptake of oxidized LDL
thereby inhibiting foam cell formation [63, 64].
Heart FABP (H-FABP, also known as M-FABP) has
been isolated from a wide range of tissues, including
cardiac muscle, skeletal muscle, renal cortex, testis
and brain [65]. Levels of H-FABP are influenced by
testosterone, exercise and circadian rhythms. The
important role of heart FABP in regulation of b-
oxidation in cardiac muscle was discovered with the
creation of mice deficient in heart FABP, which
exhibits a severe defect in cardiac myocyte long-
chain fatty acid cellular transport and b-oxidation
[66]. H-FABP has been shown to bind various fatty
acids, although some reports indicate a preference for
unsaturated fatty acids. No other ligands have been
identified for H-FABP (Table 2).
Epidermal type FABP (E-FABP, also known as
keratinocyte FABP) is expressed ubiquitously in
various tissues [40]. Similarly to A-FABP, E-FABP
binds a variety of fatty acids and synthetic compounds
with similar affinities (Table 2). The generation of E-
FABP-deficient mice demonstrated that E-FABP is
responsible for the water permeability barrier of the
skin [67]. This mild phenotype, restricted to the skin,
could be explained by the fact that E-FABP is seldom
the only FABP subtype expressed in a certain tissue.
Also, in the liver of E-FABP-deficient mice H-FABP
Table 2. Ligand binding of natural and synthetic compounds to different FABP subtypes. The table is a compilation of binding data [47, 52,
53, 84, 92–97].
n.b., no binding; n.d. not measured; + – +++ indicates increasing binding affinity.
Ligand L-FABP L-FABP A-FABP E-FABP H-FABP
Palmitic acid (16:0) +++ + ++ ++ +++
Stearic acid (18:0) + – +++ + ++ ++ +++
Palmitoleic acid (16:1) ++ + ++ ++ +++
Oleic acid (18:1) ++ – +++ + ++ ++ +++
Linoleic acid (18:2) ++ + ++ ++ ++
Linolenic acid (18:3) + – ++ + + ++ ++
AHA (20:4) ++ + + – ++ ++ ++
DHA (20:4) ++ – +++ + ++ ++ +
Phytanic acid +++ + n.d n.d n.d
15d-D12,14-PGJ2 + n.d n.b. n.d n.d
Wy14,643 ++ n.b – + n.b. n.d. n.d.
ETYA ++ ++ n.d. n.d. n.d.
Bezfibrate ++ + n.d n.d n.d
LtB4 n.b. – + n.d n.d n.d n.d
Troglitazon + n.b. – + ++ + n.d.
2468 C. Wolfrum Intracellular fatty acid sensing
is upregulated, whichmight compensate for the loss of
E-FABP. Interestingly, E-FABP itself is dramatically
increased in A-FABP-deficient adipocytes [61, 62],
indicating that these proteins are part of a highly
redundant compensatory mechanism.
FABPs and PPARs: a signaling pathway for fatty
acids
Since fatty acids have been shown to be regulators of
nuclear receptor activity, it was hypothesized that due
to the lipophilic nature of these compounds an
intracellular transport system would need to exist to
shuttle fatty acids from the cytoplasmatic membrane
to the nucleus for targeted receptor activation. Dong
et al. described such a mechanism by providing
experimental evidence that Crebp facilitates the
transport of 9-cis retinoic acid to the transcription
factor RXR for activation of the latter receptor [68].
These findings have been extended in recent years to
encompass regulation of PPAR activity by fatty acids
through cytosolic FABPs, which show ligand binding
affinity similar to their receptors.
The first study demonstrating a direct link between
FABP expression and PPAR activation was per-
formed byHertzel andBernlohr [60]. By coexpressing
PPARg andA-FABP inCV-1 cells, they demonstrated
enhanced activation of PPARg, as measured in a
reporter gene assay. This increase inPPARg activation
showed a significant positive correlation to A-FABP
expression. From these findings the authors suggested
thatA-FABP functions as a positive factor in fatty acid
signaling by directly targeting and delivering fatty
acids and/or metabolites to PPAR to activate the lipid
signal transduction pathway. Several further studies
on the regulation of PPAR activity through FABPs
were published in the following years analyzing
different pairs of FABPs/PPARs based on their
relative tissue distribution.
The L-FABP type family member was reported to
regulate activity of different PPAR subtypes in
hepatocytes. It was shown that L-FABP and PPARa
as well as PPARg colocalize to the nucleus of
hepatocytes and that both proteins interact as dem-
onstrated by direct immunoprecipitation and mam-
malian two-hybrid assays [69]. These studies, linking
activation of the nuclear receptor and FABP concen-
tration, were performed in a series of HepG2 cell
clones, which expressed L-FABP at various levels,
generated by stable antisense L-FABP transfection
[57]. PPAR activation was quantified using a reporter
gene approach, and the relationship between intra-
cellular FABP concentration and PPARa and PPARg
activation, respectively, was determined in the pres-
ence of various fatty acids and hypolipidemic drugs
which had been shown to be activators of either
receptor. The correlation of transactivation versus L-
FABP concentration revealed a positive linear corre-
lation for all fatty acids and hypolipidemic drugs
tested. Similar to PPARa a linear correlation was
found between intracellular L-FABP concentration
and PPARg activation. The observed protein-protein
interaction of L-FABP andPPARa/gwas analyzed for
its dependency on the ligand status of L-FABP, and it
was shown that the addition of either linoleic acid or
Wy14,643 did not affect the interaction of L-FABP
and PPARa. Thus it was suggested that L-FABP in the
hepatocyte functions as a transporter of fatty acids and
xenobiotics but that interaction of the two proteins is
independent of a bound ligand.
In addition to the positive correlation between PPAR
activation and FABPs, in 2000 a study was published
that put forth the hypothesis that PPARactivation and
FABPs might be inversely correlated under certain
condition [70]. The authors studied tetradecylthio-
acetic acid (TTA)-stimulated activation of all three
PPAR subtypes in response to A-FABP and E-FABP
overexpression in CV-1 cells. Under all conditions the
authors found an inverse relationship between PPAR
activation (all three subtypes) and intracellular FABP
concentration, which contrasted with the published
data so far. Interestingly, when BRL49653 was used as
an activator of PPARg, A-FABP had no significant
effect on ligand-dependent activation, whereas co-
transfection with E-FABP resulted in a decrease in
transactivation potential similar to the decrease
observed for TTA-induced transactivation. In accord-
ance with other studies they found nuclear expression
of both A-FABP and E-FABP in their experiment.
The divergent findings between this and other studies
are interesting because of the possibility that different
FABPs regulate PPAR activity in a different manner.
Since all studies that have been published so far
showing a direct correlation between FABP and
PPAR activity have been performed in cell culture
systems, it is possible that in some tissues FABPsmight
function as negative regulators of PPAR activity. One
caveat when comparing these studies to others,
however, is the ligand that was used in these experi-
ments. Although TTA is a true ligand of all the PPAR
subtypes, TTA is unable to undergo ß-oxidation thus
leading to a unphysiological buildup of the free TTA
as well as its CoA (coenzyme A) ester over the course
of the 2-day incubation This in turn might lead to
nonspecific effects, such as the repression of nuclear
receptor activity, which could explain the divergent
findings.
A more recent study on FABP-PPAR interaction was
published by Tan et al. in 2002. The authors showed
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that A-, H- and E-FABP selectively enhance the
activities of different PPAR subtypes [71]. Similar to
the above-mentioned experiments, the activity of
PPAR was measured by cotransfecting a PPAR,
responsive reporter gene together with an expression
vector for either FABP or PPAR subtype before
treating the cells with various ligands. H-FABP
augmented the transcriptional activity of PPARa
under all conditions. A-FABP markedly enhanced
the transcriptional activity of PPARg both in the
absence and in the presence of an exogenous ligand,
while the effect of E-FABPon PPARg expression was
not significant. On the other hand, E-FABPmarkedly
activated PPARß in a dose-dependent manner, while
A-FABP had no effect on the activity of this receptor.
Furthermore, the authors showed that E-FABP or A-
FABP fused with GFP upon addition of the PPARg
ligand rosiglitazone resulted in a dramatic redistrib-
ution of A-FABP into the nucleus, while E-FABP
relocated to the nucleus upon addition of the synthetic
PPARß ligand L165041. In coprecipitation FABP
experiments the authors could show a weak associa-
tion between PPARg and GST-tagged or histidine-
tagged A-FABP in the absence of ligand, but the
interaction was significantly stabilized in the presence
of the PPARg ligand troglitazone, while A-FABP did
not form an observable complexwith PPARß either in
the presence or absence of ligand. Conversely, E-
FABP associated with PPARß in the presence of the
PPARß ligand L165041, while it did not associate with
PPARg in the absence of ligand or in the presence of
either troglitazone.
Themost recent study was published in 2006 byAdida
and Spener, in which the authors analyzed the
regulation of PPARg activity by A-FABP with special
emphasis on the contribution of ligand binding to the
FABP-PPAR interaction [72]. The authors demon-
strated thatA-FABP interactedwith both the PPARg1
and g2 isoform but not with either PPARa or PPARb.
No difference was observed for the binding of A-
FABP to either PPARg1 or PPARg2. In addition to the
interaction of A-FABP they demonstrated that B-
FABP interacted with PPARg1 and PPARg2, respec-
tively, which is the first report for the interaction of
this FABP subtype with any nuclear receptor. As
shown previously by Helledie et al. [70] and Tan et al.
[71], the authors demonstrated that upon ligand
binding A-FABP translocates to the nucleus after a
4-h treatment with linoleic acid. Furthermore, the
authors demonstrated that this nuclear accumulation
is independent of putative A-FABP phosphorylation
at position Tyr19 but is directly due to ligand binding
of A-FABP. This was shown by employing a fatty
binding-deficient mutant of A-FABP (Arg126) [73].
The mutant fatty acid binding-deficient A-FABP
shows localization similar to wildtype A-FABP in
the absence of exogenous fatty acids but fails to
translocate to the nucleus in the presence of exoge-
nous fatty acids, thus demonstrating that ligand bind-
ing of A-FABP is a requirement for nuclear redis-
tribution of A-FABP. In contrast to the results
reported by Tan et al. [71], the authors of this study
did not find a ligand dependency of FABP-PPAR
interaction. This was shown by using delipidated A-
FABP bound to sepharose, which interacted with
PPARg in the same intensity independent of the
presence of exogenous ligand (Fig. 1a and b).
In summary, from the above-mentioned studies that
directly address the functional relationship between
FABPs and PPARs, it is evident that FABPs affect the
Figure 1. Effects of ligands on A-FABP/PPARg-DEF interaction.
(a) [35S]-PPAR (Input) was precipitated with A-FABP. Bound
PPAR was eluted with 2  SDS loading buffer after 3 washes with
HEDK-100 buffer. After separation of proteins by SDS-polyacry-
lamide gel electrophoresis (13.5%), radioactively labeled proteins
were visualized by autoradiography. Representative example from
2 (PPARa,b) to 3 independent experiments (PPARg1,2); (b)
ensitometric analysis of 3 independent experiments. The intensity
of the band corresponding to A-FABP-Sepharose with no ligand
was set to 100%. *Significant difference in comparison to A-
FABP-Sepharose in the absence of ligand by paired t-test
(P < 0.05). Figure taken from Adida et al. [72].
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activity of PPARs by regulating ligand availability
(Fig. 2). Discrepancies between the observed positive
correlation of FABP concentration and PPARactivity
in three studies and the negative regulation of PPAR
activity by FABPs in one study could either be due to
tissue-specific or ligand-specific differences for
FABP-regulated PPAR activity. An important ques-
tion that remains unanswered at the moment is the
ligand dependency of the interaction between PPARs
and FABPs. It was shown that the interaction between
L-FABP and PPARa is ligand-independent; however,
two conflicting studies exist with respect to A-FABP
and its interaction with PPARg [71, 72]. By using a
fatty acid binding-deficient mutant ofA-FABP,Adida
and Spener demonstrated that ligand binding of A-
FABP is in part responsible for translocation of the
protein; however, ligand-independent mechanisms
for nuclear translocation exist as well. In contrast to
the report published by Tan et al. [71] the authors
could not observe any ligand dependency of inter-
action between A-FABP and PPARg in the presence
or absence of ligand. These differences might be due
to the fact that in the study by Tan et al. coprecipi-
tation experiments were carried out with GST-tagged
proteins, while the studies byAdida et al. were carried
out by unmodified A-FABP. The use of the binding-
deficient control in the latter experiment strongly
suggests that interaction of PPARg and A-FABP is
ligand-independent. Thus at present the level of
controlling fatty acid flux to the nuclear receptor is
achieved by regulating the nuclear import of FABP by
so far unknown mechanisms.
In addition to the above-mentioned studies that
directly show a dependency of PPAR activation on
FABP, further insights into the regulation of PPAR
activity through ligand transport by fatty acid binding
proteins can be gained by comparison of genetic
models of PPAR and FABP ablation, respectively. In
the case of L-FABP it has been shown that the single
knockout of L-FABP does not affect PPARa activity
in the hepatocyte [74, 75], thus contrasting with the
observed data in cell culture. As mentioned above,
however, FABPs are part of a redundant system, and
E-FABP, which is also expressed in the hepatocyte,
might compensate for the loss of L-FABP as E-FABP
has been shown to regulate PPAR activity [71].
Furthermore, it will be necessary to study the effect
of ligand induced stimulation of PPARa above the
steady-state level asmice chow in general contains low
amounts of fatty acids. It is possible that challenging
mice with potent PPARa activators like polyunsatu-
rated fatty acids or hypolipidemic xenobiotics might
Figure 2. FABPs function as cy-
toplasmatic shuttle proteins for
ligand activation of PPARs.
Cell.Mol. Life Sci. Vol. 64, 2007 Multi-author Review Article 2471
result in differences in the levels of PPARa activation.
With respect to interaction ofA-FABP/PPARg andE-
FABP/PPARb, a clear-cut relationship seems to exist,
in the sense that either FABP can only activate one
receptor subtype. Interestingly, PPARg heterozygous
animals are resistant to obesity when challenged by a
high-fat diet [33], while A-FABP knockout animals
develop dietary obesity. But, unlike control mice, they
do not develop insulin resistance or diabetes [61, 62].
However, a caveat exists as E-FABP is upregulated
about 20-fold in these animals [62]. Furthermore,
adipocytes isolated from E-FABP-deficient mice ex-
hibit enhanced insulin-stimulated glucose transport
capacity [76], while mice expressing high levels of E-
FABP in adipose tissue display reduced systemic
insulin sensitivity [76, 77]. These findings are highly
suggestive of the fact that E-FABP plays an important
role in controlling adipocyte metabolism and might
adequately compensate for the loss of A-FABP. Mice
lacking both E-FABP and A-FABP exhibited a
striking phenotype with strong protection from diet-
induced obesity, insulin resistance, type 2 diabetes and
fatty liver disease [78]. These mice have altered
cellular and systemic lipid transport and composition,
leading to enhanced insulin receptor signaling, en-
hanced muscle AMP-activated kinase activity and
dramatically reduced liver stearoyl-CoA desaturase-1
activity underlying their phenotype [78]. This suggests
that E-FABP at a higher rate of expression may
compensate for A-FABP-dependant activation of
PPARg. On the other hand, it might be possible that
induction of E-FABP expression in accordance with
the pair specificity reported by Tan et al. [71] leads to
the induction of PPARb, resulting in the observed
phenotype. This hypothesis is in contrast to recent
findings that suggest that activation of PPARb rather
than its deletion leads to expression of genes required
for fatty acid oxidation and energy dissipation, which
in turn leads to improved lipid profiles and reduced
adiposity [35, 37].
Interestingly, a recent study using A-FABP-deficient
macrophages demonstrated that lack of A-FABP
coincided with defects in cholesterol accumulation
and alterations in pro-inflammatory responsiveness
[63]. Furthermore, these macrophages exhibited al-
tered lipid composition and enhanced PPARg activity.
The authors conclude that in normal macrophages A-
FABP would retain PPARg-activating fatty acids in
the cytosol, thereby repressing its activity. This is in
contrast to the reported in vitro data, which could be
explained either by the fact that themechanism for the
regulation of PPAR activity is tissue-specific. On the
other hand it could be possible that similar to what is
observed in adipocytes another FABP subtype, such
as E-FABP, is upregulated in these macrophages,
leading to the observed phenotype. A study by Boord
et al. seems to support this notion, as they demon-
strated that ApoE-deficient mice with genetic abla-
tion for both A-FABP and E-FABP were protected
from atherosclerosis development [78]. Thus, further
studies in macrophages using combined A-FABP/E-
FABP-deficient animals will be necessary to assess
these questions. In conclusion it must be noted that
comparison of the genetic models might not provide
good evidence for the activation of PPARs through
FABP because several pathways might regulated in a
compensatory manner, and thus the effect of this one
pathway on the whole body phenotype might be
difficult to dissect.
FABPs, as have been shown by independent studies,
seem to act as regulators of PPAR activities by
providing ligands for nuclear receptor activation.
Besides physical interaction of different pairs of
FABPs/PPARs the complexity of ligand binding and
transactivation of both PPARs and FABPs, is an
important regulation point for this signal transduction
pathway. First, all binding studies analyzing FABP-
ligand interaction have demonstrated that the binding
of fatty acids by FABPs is quite strong, and it remains
to be elucidated whether it would be possible for
PPARs to displace fatty acids bound to FABPs. L-
FABP is an exception to this problem, as it can bind
two ligands at the same time, with the second ligand
being bound with much lower affinity, which would
allow its displacement by PPARs. Other exceptions
are xenobiotic compounds, knownpotent activators of
PPARa, which have been shown to bind L-FABPwith
an approximately 10-fold weaker affinity than fatty
acids. This reflects a situation in which, under phys-
iologic conditions, ligands might not be retained by L-
FABP and therefore would be more available to bind
PPARs. The high-affinity binding of different fatty
acids to liver FABP suggests that the ligand-binding
protein complexmay represent the form inwhich fatty
acids are transported into the nucleus for possible
interaction with and delivery to the PPARs. In this
scenario, when liver FABP enters the nucleus carrying
a fatty acid and a peroxisome proliferators, the PPAR
will be able to extract the peroxisome proliferator,
whereas the fatty acid could be removed only if bound
to the low-affinity binding site. This could explain why
xenobiotics act as potent PPARa activators, despite
the presence of large amounts of fatty acids in the
cytoplasm and the nucleus. There has been some
recent evidence that PPARs can bind to and are
activated by fatty acid-CoA esters [79, 80]. Converse-
ly, it has been shown that L-FABP also binds different
fatty acid-CoA esters, albeit with lower affinity than
fatty acids [53, 81, 82]. Furthermore, it was shown that
overexpression of L-FABP in fibroblasts led to
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increased targeting of a fluorescently labeled fatty
acid-CoA ester or free fatty acids into the nuclear
membrane and nucleoplasm [82], where it colocalized
with PPARa. While this study provides only indirect
evidence for the transfer of fatty acid-CoA esters to
PPAR by L-FABP, it is of importance since fatty acid-
CoAesters are boundwith lower affinities byL-FABP
and might therefore be more readily displaced by
PPAR than the tightly bound free fatty acids. A more
comprehensive study of binding affinities of fatty acid-
CoA esters to PPARs and FABPs will be important to
assess the importance of this pathway.
The discrimination of fatty acid leads back to the
question of different fatty acid subtypes. It has been
shown in several studies that polyunsaturated long
and very long chain fatty acids are the strongest
activators of PPARs, which also correlates with the
binding of these compounds. Interestingly, these
differences are not exactly mirrored by FABPs. Even
though polyunsaturated fatty acids are usually the
preferred ligands of FABP (exception being H-
FABP), FABPs still bind the fatty acids with high
affinity. Thus it can be envisaged that the activation of
PPARs through EFAs and other important polyunsa-
turated fatty acids which have been shown to be
beneficial for health with respect to diabetes and
obesity is due to the fact that FABPs discriminate
between these fatty acids. It is tempting to speculate
that polyunsaturated fatty acids would be more read-
ily transferred to PPARs for target gene activation,
while medium and short chain saturated fatty acids
were retained by FABPs. In this simplistic view,
activation of PPAR through unsaturated fatty acids
would lead to increased lipid metabolism, while
saturated fatty acids would be retained by FABPs
and stored, leading to the development of obesity and
insulin resistance.
In conclusion it has to be noted that in vitro evidence
for a pathway linking FABPs and PPARs with respect
to signal transduction has been proven by a number of
independent studies (Fig. 2). The exactmechanism for
how FABPs are translocated to the nucleus upon
ligand binding andhowa ligand is transferred between
FABP and PPAR remains unclear. Furthermore, a
direct link between in vivo data gained from studying
the genetic knockout models of either PPARs or
FABPs remain inconclusive,most likely due to the fact
that several compensatory mechanisms exist which
may influence and deregulate a severe phenotype like
complete ablation of either FABP or PPAR expres-
sion. Further studies of these pathways will be needed,
as it is evident that PPARs control several major
aspects of glucose and lipid metabolism as evidenced
by the fact that several important drugs to counter
obesity and diabetes are targeted towards those
receptors. It will be of utmost importance to under-
stand the exact mechanism of delivery of these drugs,
as the transfer proteins pose one discriminatory step in
translocation of those compounds from the extracel-
lular compartment to the nucleus for receptor activa-
tion and thus play an important role in modulating
receptor activity.
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